Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Total Current Liabilities of $153.8 million for Q2 2026, up 67.47% year-over-year from $91.8 million in Q2 2025, and up 22.98% quarter-over-quarter from $125.0 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Total Current Liabilities for 9 consecutive years, with $153.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities rose 67.47% year-over-year to $153.8 million; the TTM figure through Jun 2026 stood at $153.8 million (up 67.47% YoY), while the FY2025 annual figure was $132.0 million, up 54.03% from the prior year.
- Total Current Liabilities climbed to $153.8 million in Q2 2026 per PHAT's latest filing, from $125.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $153.8 million in Q2 2026 and bottomed at $11.4 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $60.6 million across 5 years, with a median of $45.2 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 72.1% — and 2024, when it surged 200.9%.
- Phathom Pharmaceuticals' Total Current Liabilities stood at $26.2 million in 2022, then jumped by 47.81% to $38.8 million in 2023, then jumped by 121.06% to $85.7 million in 2024, then soared by 54.03% to $132.0 million in 2025, then grew by 16.46% to $153.8 million in 2026.
- Business Quant data shows PHAT's Total Current Liabilities at $153.8 million in Q2 2026, $125.0 million in Q1 2026, and $132.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 153.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 153.78 Mn |
| Mar 31, 2026 | 125.04 Mn |
| Dec 31, 2025 | 132.04 Mn |
| Sep 30, 2025 | 93.12 Mn |
| Jun 30, 2025 | 91.82 Mn |
| Mar 31, 2025 | 74.03 Mn |
| Dec 31, 2024 | 85.73 Mn |
| Sep 30, 2024 | 65.29 Mn |
| Jun 30, 2024 | 47.01 Mn |
| Mar 31, 2024 | 43.46 Mn |
| Dec 31, 2023 | 38.78 Mn |
| Sep 30, 2023 | 23.98 Mn |
| Jun 30, 2023 | 21.55 Mn |
| Mar 31, 2023 | 14.44 Mn |
| Dec 31, 2022 | 26.24 Mn |
| Sep 30, 2022 | 22.88 Mn |
| Jun 30, 2022 | 21.08 Mn |
| Mar 31, 2022 | 11.39 Mn |
| Dec 31, 2021 | 18.92 Mn |
| Sep 30, 2021 | 27.81 Mn |